The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers

The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers

Sortilin (SORT1) receptor-mediated endocytosis functions were exploited for this new approach for effective and safe treatments of gynecological cancers. Here, high expression of SORT1 was found in >75% of the clinically annotated ovarian and endometrial tumors analyzed by immunohistochemistry. T...

Full description

Bibliographic Details
Main Authors: Jean-Christophe Currie, Michel Demeule, Cyndia Charfi, Alain Zgheib, Alain Larocque, Bogdan Alexandru Danalache, Amira Ouanouki, Richard Béliveau, Christian Marsolais, Borhane Annabi
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Cancers
Subjects:
gynecological cancers
peptide-drug conjugates
docetaxel
sortilin
Online Access:https://www.mdpi.com/2072-6694/14/8/1877

Similar Items

Similar Items